{"entity":{"id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of IN10018 in melanoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.","summary":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06708663 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 124 participants planned, started 2025-01-17 and due to reach its primary completion in 2027-12-31. Interventions recorded: HX009+IN10018. Conditions listed: Biliary Tract Cancer, Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06708663","url":"https://clinicaltrials.gov/study/NCT06708663"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["in10018"],"companies":["hangzhou-hanx-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06708663","phase":"1/2","setting":"Phase IIa Study of HX009+IN10018 in Patients With Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated With or Without Standard Chemotherapy","sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","enrolled":124,"outcomes":[]},"route":"/trials/nct06708663/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"company":[{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/"}]}}